Increased TRPM2 in tumors may be both a driver of high FOXM1 and the embryonic stem cell program seen in non-MYCN amplified Stage 4 neuroblastoma patients, contributing to increased metastasis and worse outcome43. The gene discussed is MYCN; the disease is neuroblastoma.